|
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3494-3500.
Prepublished online as a Blood First Edition Paper on August 12, 2004; DOI 10.1182/blood-2004-05-2008.
 Previous Article | Next Article 
Submitted May 27, 2004
Accepted July 8, 2004
Thirty years of hemophilia treatment in the Netherlands, 1972-2001
Iris Plug, Johanna G van der Bom, Marjolein Peters, Evelien P Mauser-Bunschoten, Arja de Goede-Bolder, Lily Heijnen, Cees Smit, Jeannette E Zwart-van Rijkom, Jose Willemse, and Frits R Rosendaal*
Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
University Medical Center Utrecht, Van Creveldkliniek, Utrecht, The Netherlands
Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands
University Medical Center Utrecht, Van Creveldkliniek, Utrecht, The Netherlands; Rehabilitation Center "De Trappenberg", Huizen, The Netherlands
Netherlands Hemophilia Society, Badhoevedorp, The Netherlands
Hospital Pharmacy Noordoost-Brabant, 's-Hertogenbosch, The Netherlands
Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; Thrombosis and Hemostasis Research Center, Leiden University Medical Center, Leiden, The Netherlands
* Corresponding author; email: F.R.Rosendaal{at}lumc.nl.
Since the introduction of replacement therapy in the early 1960s by the infusion of plasma-derived factor VIII and IX preparations important changes have occurred for hemophilia patients. We studied the medical and social developments over thirty years of hemophilia treatment.
Since 1972 five cross-sectional national postal surveys among all hemophilia patients in the Netherlands were performed, latest in 2001. The prestructured questionnaires included items on treatment, the presence of inhibitory antibodies against factor VIII or IX, the annual number of bleeding episodes, use of inpatient hospital care and hepatitis C and HIV infections.
Response rate in 2001 was 70%. Young patients (<16 yrs) with severe hemophilia showed the largest increase in use of prophylaxis, from 34% in 1972 to 86% in 2001. The occurence of hemorrhages has gradually decreased. Hospital admissions decreased from 47% of all patients in 1972 to 18% in 2001.
Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Plug, M. Peters, E. P. Mauser-Bunschoten, A. de Goede-Bolder, L. Heijnen, C. Smit, J. Willemse, F. R. Rosendaal, and J. G. van der Bom
Social participation of patients with hemophilia in the Netherlands
Blood,
February 15, 2008;
111(4):
1811 - 1815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kang, L. Xie, D. T. Tran, C. S. Stein, M. Hickey, B. L. Davidson, and P. B. McCray Jr
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer
Blood,
September 1, 2005;
106(5):
1552 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Khallou-Laschet, G. Caligiuri, E. Tupin, A.-T. Gaston, B. Poirier, E. Groyer, D. Urbain, S. Maisnier-Patin, R. Sarkar, S.V. Kaveri, et al.
Role of the Intrinsic Coagulation Pathway in Atherogenesis Assessed in Hemophilic Apolipoprotein E Knockout Mice
Arterioscler Thromb Vasc Biol,
August 1, 2005;
25(8):
e123 - e126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
